Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData, Phase III drugs for Metastatic Colorectal Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Eniluracil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eniluracil overview

Eniluracil is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer and pancreatic cancer. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase. It was also under development for hepatocellular carcinoma , non-small cell lung carcinoma, gastric cancer, cervical cancer, prostate cancer.

Processa Pharmaceuticals overview

Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.

For a complete picture of Eniluracil’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.